Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Gemcitabine + Cisplatin Neoadjuvant Chemotherapy in Resectable Locally Advanced HNSCC
NCT04947241Phase 1Active, not recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2020
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Major Pathological Response Rate, Objective Response Rate and 2 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04947241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04947241.